Median follow-up from the start of therapy for metastatic ALK+ NSCLC for our alectinib-treated patients (n = 19, Table 1) was 57 months (95% confidence interval (CI) 28.1–86.1 months), while their median OS was not reached (3/19 events so far). The gene discussed is ALK; the disease is non-small cell lung carcinoma.